EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Changing incentives to ACCELERATE drug development for paediatric cancer

Teresa de Rojas iD, Pamela Kearns, Patricia Blanc, Jeffrey Skolnik, Elizabeth Fox, Leona Knox iD, Raphael Rousseau, François Doz, Nick Bird, Andrew J Pearson, Gilles Vassal

Cancer Medicine · 2023-04 · 12 (7) · 8825-8837

DOI: 10.1002/cam4.5627 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 16.01.2023. Verfasst von Teresa de Rojas und 10 weiteren Autor:innen. Beteiligte Einrichtung: ACCELERATE, Brussels, Belgium. Hauptthemen laut MEDLINE: Motivation, Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Andrew McDonough B+ Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

More effective incentives are needed to motivate paediatric oncology drug development, uncoupling it from dependency on adult drug development. Although the current European and North‐American legislations aim to promote drug development for paediatrics and rare diseases, children and adolescents with cancer have not benefited as expected from these initiatives and cancer remains the first cause of death by disease in children older than one. Drug development for childhood cancer remains dependent on adult cancer indications and their potential market. The balance between the investment needed to execute a Paediatric Investigation Plan (PIP) in Europe and an initial Paediatric Study Plan (iPSP) in the US, coupled with the potential financial reward has not been sufficiently attractive to incite the pharmaceutical industry to develop drugs for rare indications such as childhood cancer.

Methods

We propose changes in the timing and nature of the rewards within the European Paediatric Medicine Regulation (PMR) and Regulation on Orphan Medicinal Products (both currently under review), which would drive earlier initiation of paediatric oncology studies and provide incentives for drug development specifically for childhood indications.

Results

We suggest modifying the PMR to ensure mechanism‐of‐action driven mandatory PIP and reorganization of incentives to a stepwise and incremental approach. Interim and final deliverables should be defined within a PIP or iPSP, each attracting a reward on completion. A crucial change would be the introduction of the interim deliverable requiring production of paediatric data that inform the go/no‐go decisions on whether to take a drug forward to paediatric efficacy trials.

Conclusion

Additionally, to address the critical gap in the current framework where there is a complete lack of incentives to promote paediatric‐specific cancer drug development, we propose the introduction of early rewards in the Orphan Regulation, with a variant on the US‐Creating Hope Act and its priority review vouchers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MotivationNeoplasmsAdolescentAdultChildHumansDrug DevelopmentMedical OncologyDrug Industry

Stichwörter der Autor:innen

drug developmentincentivespaediatric oncologypaediatric regulationsupplementary protection certificate

Autor:innen und Institutionen

  • ACCELERATE, Brussels, Belgium.
  • Cancer Research UK Clinical Trials Unit, National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, Institute of Cancer and Genomic Sciences, Birmingham, UK.
  • Imagine for Margo - Children Without Cancer, Saint-Germain-en-Laye, France.
  • INOVIO Pharmaceuticals, Inc., Plymouth Meeting, Pennsylvania, USA.
  • St Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Solving Kids' Cancer UK, London, UK.

ORCID-Profile: Teresa de Rojas, Leona Knox

Förderung

  • Andrew McDonough B+ Foundation

Zitieren

APA

de Rojas, T., Kearns, P., Blanc, P., Skolnik, J., Fox, E., Knox, L., Rousseau, R., Doz, F., Bird, N., Pearson, A. J., & Vassal, G. (2023). Changing incentives to ACCELERATE drug development for paediatric cancer. Cancer Medicine, 12(7), 8825-8837. https://doi.org/10.1002/cam4.5627

Vancouver

de Rojas T, Kearns P, Blanc P, Skolnik J, Fox E, Knox L, et al. Changing incentives to ACCELERATE drug development for paediatric cancer. Cancer Medicine. 2023;12(7):8825-8837. doi:10.1002/cam4.5627

BibTeX
@article{deRojas2023,
  author = {de Rojas, Teresa and Kearns, Pamela and Blanc, Patricia and Skolnik, Jeffrey and Fox, Elizabeth and Knox, Leona and Rousseau, Raphael and Doz, François and Bird, Nick and Pearson, Andrew J and Vassal, Gilles},
  title = {Changing incentives to ACCELERATE drug development for paediatric cancer},
  journal = {Cancer Medicine},
  year = {2023},
  volume = {12},
  number = {7},
  pages = {8825--8837},
  doi = {10.1002/cam4.5627}
}
Kostenlos starten →